Cargando…
Idebenone does not inhibit disability progression in primary progressive MS
BACKGROUND: Multiple sclerosis (MS) is a chronic, immune-mediated neurodegenerative disorder of the central nervous system (CNS). While current MS therapies target the inflammatory processes, no treatment explicitly targets mitochondrial dysfunction and resulting axonal loss. Therefore, the aim of t...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386688/ https://www.ncbi.nlm.nih.gov/pubmed/32784117 http://dx.doi.org/10.1016/j.msard.2020.102434 |